GLP-1 Upgrade: NA-931 Phase 2 Results ARE IN: Builds Muscle & Burns Fat

NA-931: Tackling the Muscle Loss Problem Head-On

Dr. Richard Visser covers NA-931, a next-generation compound that claims to address one of the biggest criticisms of current GLP-1 medications: the loss of lean muscle mass during treatment. The pitch is straightforward. Current GLP-1s make you lose weight, but a meaningful percentage of that weight is muscle, more than fat. NA-931 is designed to shift that ratio, burning more fat while preserving or even building muscle. If it delivers on that promise, it would fix the single biggest limitation of the current GLP-1 class.

The muscle-loss concern with GLP-1s is well-documented. Studies of semaglutide and tirzepatide consistently show that roughly 25-40% of total weight lost is lean mass. For older patients, patients with lower baseline muscle mass, or patients not engaged in resistance training, this muscle loss can have real functional consequences: reduced strength, impaired mobility, lower metabolic rate, and potentially increased frailty. The medical community has been looking for ways to mitigate this, and NA-931 represents a pharmacological approach rather than relying solely on exercise and dietary protein to protect muscle.

Dr. Visser explains that NA-931 works through a mechanism that goes beyond simple GLP-1 receptor activation. The drug incorporates properties that interact with pathways involved in muscle protein synthesis and fat oxidation. The specific details of the mechanism are not fully disclosed (common for drugs in early development), but the biological approach targets the anabolic pathways that promote muscle growth while simultaneously targeting the catabolic pathways that break down fat. If this sounds like the pharmaceutical equivalent of body recomposition, that is essentially what it is aiming for.

The Phase 2 Results That Generated Buzz

The Phase 2 data for NA-931 included body composition measurements using DEXA scanning, which is the gold standard for distinguishing between fat mass and lean mass changes. The results showed that patients on NA-931 lost significant fat mass while maintaining or slightly increasing lean mass. This is a strikingly different profile from existing GLP-1s, where lean mass loss typically tracks proportionally with total weight loss.

Dr. Visser breaks down the numbers with appropriate context. The total weight loss was competitive with existing GLP-1s, but the body composition of that weight loss was dramatically different. Patients were more than getting lighter; they were getting leaner in the truest sense. The fat-to-lean ratio of weight loss was substantially better than what has been seen with semaglutide or tirzepatide in their respective trials.

The metabolic markers also looked promising. Beyond weight and body composition, participants showed improvements in insulin sensitivity, lipid profiles, and inflammatory markers that were consistent with, or in some cases better than, the improvements seen with existing GLP-1 medications. Dr. Visser suggests that the muscle preservation component may contribute to better metabolic outcomes because muscle tissue is a major site of glucose disposal and metabolic activity.

Why This Matters Beyond the Numbers

Dr. Visser makes a compelling case for why a muscle-preserving GLP-1 would change the treatment calculus. Right now, the standard advice for GLP-1 patients is to engage in regular resistance training and eat high-protein diets to mitigate muscle loss. This is good advice, but not everyone follows it, and even those who do still experience some lean mass reduction. A drug that handles the muscle preservation pharmacologically would be especially valuable for patients who are unable to exercise (due to mobility limitations, injuries, or other health conditions) or who simply will not maintain a consistent strength training program.

There is also an aging angle here. As people get older, muscle mass naturally declines (sarcopenia), and the combination of obesity and sarcopenia (sometimes called sarcopenic obesity) is one of the most challenging clinical scenarios in geriatric medicine. A drug that reduces fat while preserving muscle would be nearly ideal for this population, who currently face a difficult trade-off between losing weight (which reduces metabolic disease but accelerates muscle loss) and maintaining muscle (which supports function but may mean living with excess fat).

The presenter also discusses the potential for NA-931 to find applications beyond pure weight loss. Athletes, individuals recovering from illness-related muscle wasting, and aging populations interested in body recomposition could all theoretically benefit from a compound that simultaneously promotes fat loss and muscle maintenance. Whether the regulatory pathway would support these broader applications is a separate question, but the biological potential is there.

What to Be Cautious About

Dr. Visser is enthusiastic but includes appropriate disclaimers. Phase 2 data, particularly from a relatively small trial, can look dramatically better than Phase 3 results in larger, more diverse populations. The muscle-building claims need to be validated in much larger studies with longer follow-up. The safety profile also needs more data. Any compound that affects muscle protein synthesis pathways needs thorough evaluation for effects on the heart (which is, after all, a muscle) and for any cancer-related signals (since pathways that promote growth can theoretically promote unwanted growth as well).

The video also acknowledges that NA-931 is earlier in development than many of the drugs that get more media attention. The timeline to market, if everything goes perfectly, is still several years out. For patients who need treatment now, this is interesting future context rather than an imminent option.

The implications of muscle preservation during weight loss extend beyond aesthetics and functional capacity. Skeletal muscle is the body's largest glucose disposal organ, meaning it plays a primary role in pulling sugar out of the bloodstream and storing it as glycogen. When you lose muscle mass during weight loss, you reduce your body's capacity to manage blood sugar, which is counterproductive for a treatment that is partly aimed at improving metabolic health. A drug that preserves muscle while reducing fat maintains the body's glucose disposal capacity, which should translate into better long-term metabolic outcomes even after treatment ends. This metabolic argument for muscle preservation is independent of the functional and quality-of-life arguments, and it provides a strong biological rationale for why NA-931's approach matters clinically.

The muscle preservation question is also relevant to the long-term maintenance question. One of the reasons weight regain is so common after stopping GLP-1 medications is that the muscle lost during treatment reduces resting metabolic rate, creating an energy balance that favors weight regain. If NA-931 preserves muscle during the treatment phase, patients who eventually discontinue the medication should have a higher resting metabolic rate than they would have had after losing the same amount of total weight on a conventional GLP-1. This higher metabolic rate provides a larger caloric buffer, meaning the patient can eat more without regaining weight. The magnitude of this effect is still theoretical at this stage, but the directional logic is sound and has the potential to change how we think about post-treatment maintenance.

Dr. Visser's point about the potential applications beyond obesity is intriguing but requires careful framing. The regulatory pathway for a drug indication requires clinical trials specifically designed for that indication. Even if NA-931 shows muscle-preserving benefits in obesity trials, those results do not automatically translate into approved use for sarcopenia, cancer cachexia, or age-related muscle loss. Each of these conditions would require separate clinical trials with appropriate patient populations, endpoints, and safety monitoring. That said, the biological mechanism that enables muscle preservation in obesity patients is likely the same mechanism that would provide benefit in these other conditions, so the clinical development potential is genuine even if the timeline is uncertain.

One safety consideration that deserves ongoing attention is the effect of muscle-promoting pathways on cardiac tissue. The heart is a muscle, and any drug that promotes muscle growth or preservation needs to be carefully evaluated for cardiac effects, both beneficial and harmful. Increased cardiac muscle mass (hypertrophy) can be physiological (healthy adaptation) or pathological (disease-related), and distinguishing between the two requires careful monitoring with echocardiography and other cardiac imaging. The Phase 2 data did not raise cardiac safety signals, which is reassuring, but this is an area where longer-term data from larger populations will be needed before clinicians and patients can be fully confident about the cardiac safety profile.

Questions to Watch

Key questions for NA-931's ongoing development: Does the muscle preservation hold up in Phase 3 trials with larger and more diverse patient populations? Is the effect size clinically meaningful for patients at high risk of sarcopenia? What is the long-term safety profile, particularly regarding cardiac and oncological endpoints? Will the drug be positioned primarily for weight loss, or will it pursue additional indications? And how does the cost compare to existing GLP-1s given the additional manufacturing complexity?

Who Should Watch This

This video is most relevant for people concerned about muscle loss on GLP-1 therapy, which should honestly be most GLP-1 users. If you are over 50, have mobility limitations, or have struggled to maintain muscle mass during weight loss, the concept behind NA-931 is directly relevant to your situation. Prescribers who manage older or sarcopenic patients will find the body composition data particularly interesting. For the general audience, this video provides a clear introduction to what could be the most patient-relevant innovation in the next wave of GLP-1 development: drugs that help you lose fat without losing the muscle you need to function well.